Re: Efficacy and Safety of VPM1002 and Immuvac in Preventing Tuberculosis: Phase 3 Randomised Clinical Trial (PreVenTB Trial)

Why It Matters

The critique calls into question premature policy recommendations for these TB vaccines and stresses rigorous statistical standards for future trials, affecting funding and public‑health strategies.

Key Takeaways

• Primary endpoint missed: no significant reduction in confirmed TB.
• Reported 50% efficacy for extrapulmonary TB based on 12 vs 24 cases.
• Subgroup analyses lack multiplicity correction, risk inflated effect sizes.
• Bayesian re‑analysis lowers extrapulmonary efficacy estimate to ~30%.
• Authors call for hypothesis‑generating view and pre‑planned Bayesian checks.

Pulse Analysis

Tuberculosis remains a leading infectious killer, and the search for an effective vaccine is a global priority. The PreVenTB trial, a large phase‑3 study of two novel candidates—VPM1002 and Immuvac—promised a potential breakthrough, but its primary outcome—preventing microbiologically confirmed TB—showed no statistically meaningful benefit. This failure is a sobering reminder that even promising immunogenic platforms must demonstrate real‑world protection before influencing national immunization programs.

The rapid response from Biswas and colleagues spotlights a common statistical pitfall: over‑interpreting post‑hoc subgroup findings. With only a dozen extrapulmonary TB events among vaccine recipients, the reported 50% efficacy carries a wide confidence interval and lacks adjustment for multiple comparisons. Such sparse data are prone to Type M (magnitude) and Type S (sign) errors, inflating perceived benefits. By applying a weakly informative Bayesian prior centered on no effect, the authors show the posterior median efficacy drops to about 30%, and the probability of exceeding that threshold is merely 50%, suggesting the original claim is not robust.

For stakeholders—pharmaceutical developers, funders, and public‑health agencies—this analysis underscores the necessity of pre‑specified Bayesian sensitivity checks and transparent reporting standards. Future TB vaccine trials should embed multiplicity‑adjusted analyses and treat any subgroup signal as hypothesis‑generating until confirmed in adequately powered studies. Adopting these rigorously vetted methods will safeguard resources, maintain scientific credibility, and ultimately accelerate the delivery of a truly effective TB vaccine to the populations that need it most.